- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05176834
Photobiomodulation Home-use Device for Prevention or Treatment of Oral Mucositis in Patients With Head&Neck Malignancies (PBM&OM-01)
Self-applied Photobiomodulation Therapy With a Home-use Device for the Prevention and/or Acceleration of Healing of Radiation-induced Oral Mucositis in Patients With Head and Neck Malignancies - A Feasibility Study
Patients with head and neck malignancy that are treated with Radiation Therapy [RT] are expected to develop Oral Mucositis (OM) in 60% of cases. Mucositis is a side effect of radiation and / or chemotherapy that causes severe pain and inability to eat and drink and a decrease in quality of life. In addition it may impair the treatment protocol and treatment outcomes.
Photobiomodulation is a non-ionizing optical radiation in the near or near-infrared range used for acceleration of wound healing and pain reduction. Photobiomodulation therapy for the reduction of mucositis is included in the International Guidelines of the MASCC / ISOO Association and the British NICE. To date the treatment has been performed by members of professional medical staff in hospitals or clinics.
The study device is home-used photobiomodulation device approved for indications of pain reduction and acceleration of wound healing. The device has shown efficacy in treating mucositis around dental implants in a clinical trial and after oncological treatments in a limited number of cases as reported in the scientific literature.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Saeed Salman, MD
- Phone Number: 050-3581987
- Email: sa_salman@rambam.health.gov.il
Study Locations
-
-
-
Haifa, Israel, 3109601
- Recruiting
- Rambam Medical Center
-
Contact:
- Saeed Salman, MD
- Email: sa_salman@rambam.health.gov.il
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with malignant neoplasm in the oral cavity, pharynx or salivary glands.
The patient should receive a continuous course of radiation therapy (IMRT) with all of the following criteria applicable:
- For a period of 3-7 weeks, 5-6 fractions per week.
- A minimum cumulative dose of 30Gy expected to cause OM (ORAL MUCOSITIS) by the third week. Or: Based on the clinical judgment of the Radiation Oncologist and BED2 ≥ 30 Gy
- The treatment field will include at least one oral site (buccal mucosa, floor of mouth, tongue, hard palate, retro-molar trigon, lips or oropharynx)
- With or without chemotherapy and / or immunotherapy at the same time.
- A patient with an ECOG PS functional status equal to or less than 2
- Able to read and understand the informed consent form (ICF) and voluntarily provided informed consent
- The patient is able to undergo intra-oral treatments
- The patient is willing to perform the protocol.
Exclusion Criteria:
- The patient underwent previous radiation to the current therapeutic field
- The patient has health conditions of the teeth or mouth that will prevent the application of intra-oral treatment
- The patient receives non-standard treatment for mucositis such as benzidamine, palifermin, etc.
- The patient is enrolled to any other clinical trial that includes treatment or intervention that may affect the course of mucositis.
- The patient has a diagnosis that affects the healing of wounds (eg diabetes, lupus, etc.)
- Pregnancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: B-Cure laser pro
In case of appearance of mucositis, patients will receive standard treatment as usual (rinses, painkillers, etc.).
In addition, study participants will treat themselves with the B-Cure laser pro before each radiation therapy session at the clinic and will continue with daily treatment until the disappearance of the mucositis should it develop.
|
The B-Cure laser pro is a portal, non-invasive, photobiomodulation device, that emits light in the near infrared (808nm) over an area of 1X4.5 cm2 with power output of 250mW, and energy dose of 1J/cm2.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of patients performing at least 50% of expected daily treatments during radiotherapy period.
Time Frame: 7 weeks
|
The patients are expected to treat themselves 5 times a week during the 7 week period of radiotherapy, accumulating to a total of 35 treatments.
The date of each treatment will be documented in a diary.
The number of treatment actually done divided by the 35 expected treatments will be calculated.
The outcome is the proportion of patients that will treat themselves at least 18 treatments out of the 35 expected (at least 50%).
|
7 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of the patients that will experience severe oral mucositis
Time Frame: 7 weeks
|
The proportion of the patients that will experience severe oral mucositis defined as grade 3 or 4 of the World Health Organization (WHO) grading for oral mucositis, according to the following: Grade 0=the patient has no signs and symptoms; Grade 1=painless ulcers, edema, or mild soreness; Grade 2=painful erythema, edema, or ulcers but able to eat; Grade 3=painful erythema, edema, or ulcers but unable eat; Grade 4=requires parenteral or enteral support |
7 weeks
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 0183-21-RMB
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Head and Neck Cancer
-
Robert FerrisAmgenCompletedHead and Neck Cancer | Cancer of Head and Neck | Head Cancer | Neck Cancer | Neoplasms, Head and Neck | Cancer of the Head and Neck | Cancer of Neck | Upper Aerodigestive Tract Neoplasms | Neck Neoplasms | Cancer of the Head | Cancer of the Neck | UADT Neoplasms | Cancer of Head | Head Neoplasms | Head, Neck Neoplasms | Neoplasms, Head and other conditionsUnited States
-
Assiut UniversityRecruitingHead and Neck Cancer | Head and Neck Neoplasms | Cancer of Head and Neck | Neoplasms, Head and Neck | Cancer of the Head and NeckEgypt
-
Mayo ClinicRecruitingCancer Head Neck | Cancer Neck | Cancer, HeadUnited States
-
IRCCS Policlinico S. MatteoNestlé Health Science Spain; Akern SrlCompletedHead-neck CancerItaly
-
University of California, San FranciscoCompleted
-
Chinook Therapeutics, Inc. (formerly Aduro)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)TerminatedHead And Neck CancerUnited States
-
National Cancer Institute (NCI)TerminatedRecurrent Head and Neck Cancer | Metastatic Head and Neck CancerUnited States
-
Radboud University Medical CenterUnknown
-
Centre Oscar LambretUnknownEpidermoid Head and Neck CancerFrance
Clinical Trials on B-Cure laser pro
-
Tel-Aviv Sourasky Medical CenterUnknown
-
Erika Carmel ltdNot yet recruitingDiabetic Foot UlcerIsrael
-
Scarborough Rouge HospitalRecruitingDiabetic Foot UlcerCanada
-
Erika Carmel ltdNot yet recruiting
-
Erika Carmel ltdTel-Aviv Sourasky Medical CenterRecruitingDiabetic Foot UlcerIsrael
-
Erika Carmel ltdHoly Family Hospital, Methuen, MACompletedRotator Cuff TearsIsrael
-
Hillel Yaffe Medical CenterUnknown
-
Erika Carmel ltdHoly Family Hospital, Nazareth, IsraelRecruiting
-
Hadassah Medical OrganizationUnknownDiabetic Foot UlcerIsrael
-
Al-Azhar UniversityEnrolling by invitationRoot Resorption of Maxillary IncisorsEgypt